Get startedLog in
    Picture of Klaria Pharma Holding AB (publ) logo

    KLAR — Klaria Pharma Holding AB (publ) News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapSucker Stock
    All News

    Brief: Klaria Pharma Holding Launches Clinical Program For Naloxone Alginatefilm Against Opioid Overdose

    Picture of Klaria Pharma Holding AB (publ) logoKlaria Pharma Holding AB (publ)
    01/07/2020 08:58
    July 1 (Reuters) - Klaria Pharma Holding AB (publ)
 KLAR.ST :
    * LAUNCHES CLINICAL PROGRAM FOR NALOXONE ALGINATEFILM
AGAINST
OPIOID OVERDOSE
    * CLINICAL DOSING STUDY SCHEDULED TO BEGIN DURING 2020
    * ESTIMATES THE TOTAL ADDRESSABLE MARKET FOR CO-PRESCRIPTION
OF
NALOXONE IS WORTH 1.9 BILLION USD IN THE UNITED STATES ALONE
    * WE ARE PLANNING TO APPLY FOR MARKET APPROVAL IN EUROPE AND
THE
UNITED STATES IN 2023

Source text for Eikon:  ID:nWkr3JmG69 
Further company coverage:  KLAR.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))

    Recent news on Klaria Pharma Holding AB (publ)

    See all news